Abstract 4278
Background
Specific anatomical locations of melanoma mets (MM) influence OS in pts treated with anti-PD-1 based immunotherapy (IT), but little is known about anatomical distribution of mets within a patient (patterns of MM). We investigated the clinical factors and OS associated with the patterns of MM.
Methods
Demographics, disease characteristics and patient outcomes were examined from MM pts. Univariate and multivariable (MVA) logistic regression was used to identify factors associated with patterns of MM. Cox proportional hazards method for OS analysis.
Results
6031 MM pts were studied; median age of 61yo, 66% male, 32% elevated LDH, 74% stage IV M1c/d. 17% had systemic treatment; IT (61%), targeted therapy (32%) and chemotherapy (7%) 1st line. Median FU was 57.5 months (mos) and the median OS (mOS) was 9.4 mos (untreated: 7.5 mos; treated: 39.4 mos). In MVA performed on untreated pts, elevated LDH (HR 1.5) and presence of brain (HR 1.5), liver (HR 1.8) and bone (HR 1.5) mets were associated with shorter OS; while gastrointestinal (GI) mets (HR 0.8) were associated with longer OS. Similar results were found for treated pts; but male pts had shorter OS (HR 1.3) and GI mets did not affect OS. Within all pts, mOS for pts with vs without brain mets was 8 vs 10 mos (p < 0.01), respectively; and mOS for pts with vs without liver mets was 7 vs 11 mos (p < 0.01), respectively. In untreated pts, brain mets were associated with adrenal mets, but not liver, GI, bone or subcutaneous (subcut); while in treated pts brain mets were associated with adrenal and subcut mets. Liver mets occurred frequently with bone, adrenal and spleen mets, and less frequently with brain, GI and subcut mets in untreated pts; while they were associated with bone and spleen mets in treated pts. Untreated pts with brain, liver or bone mets had longer mOS in the presence of GI mets (7 vs 11; 6 vs 8; 7 vs 11mos, respectively), while GI mets did not affect OS in treated pts. Treated pts with liver mets have shorter OS (22 mos) if bone (18 mos), adrenal (14 mos) or spleen (18 mos) mets are present, but this was not seen in untreated pts.
Conclusions
Both treated and untreated pts have distinct patterns of MM and survival. These data may help defining prognosis and provides insight to further studies on the biology of mets.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Melanoma Institute Australia.
Funding
Has not received any funding.
Disclosure
M.S. Carlino: Advisory / Consultancy: MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: BMS; Advisory / Consultancy: Amgen; Advisory / Consultancy: Pierre Fabre. A.M. Menzies: Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre Fabre. G.V. Long: Advisory / Consultancy: Amgen; Advisory / Consultancy: Mass-Array; Advisory / Consultancy: BMS; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Roche; Advisory / Consultancy: Aduro. All other authors have declared no conflicts of interest.
Resources from the same session
3047 - Health-related quality of life in Greek haematogical malignancies patients undergoing chemotherapy
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract
1121 - Experiences of endocrine therapy after breast cancer surgery
Presenter: Susanne Ahlstedt Karlsson
Session: Poster Display session 3
Resources:
Abstract
2305 - The effects of progressive muscle relaxation and mindfulness meditation on fatigue, coping styles, and quality of life in breast cancer patients receiving adjuvant paclitaxel regimen: An-assessor blinded, three-arm randomized controlled trial
Presenter: Zehra Gok Metin
Session: Poster Display session 3
Resources:
Abstract
4561 - Agreement between breast cancer patients and oncologists on the severity of patients’ symptoms and functions during a one-year follow-up after treatment.
Presenter: Randi Reidunsdatter
Session: Poster Display session 3
Resources:
Abstract
1768 - Taste Changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Gulcan Bagcivan
Session: Poster Display session 3
Resources:
Abstract
1830 - CART-19: a comparative between literature versus experience
Presenter: Cassandra Andersson Vila
Session: Poster Display session 3
Resources:
Abstract
4027 - Unplanned emergency department use by people receiving ambulatory anti-cancer agents with potential febrile neutropenia
Presenter: Meritxell Casanovas-Blanco
Session: Poster Display session 3
Resources:
Abstract
4754 - Examining the benefits of medical exercise during radiotherapy in patients after mastectomy
Presenter: Nikolina Dodlek
Session: Poster Display session 3
Resources:
Abstract
2510 - Assessment Quality of Life with Hand-Foot Syndrome Induced by Apatinib Combined with Anti-PD-1 Therapy in NSCLC
Presenter: Qi Jiang
Session: Poster Display session 3
Resources:
Abstract
2989 - Adverse effects of chemotherapy influence the patients’ quality of life : Analysis of implicated factors
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract